582 F.Supp.3d 26
N.D.N.Y.2022Background
- Novartis owns U.S. Patent No. ’631 covering terminally sterilized, prefilled syringes (PFS) for anti‑VEGF ophthalmic treatments; Regeneron launched an EYLEA PFS and Novartis sued for infringement.
- Regeneron alleges it and contract manufacturer Vetter co‑developed an EYLEA PFS under a Development Agreement that purportedly vested inventions by Vetter/Regeneron in Regeneron.
- Regeneron contends Novartis and Vetter conspired: Novartis obtained the ’631 patent while omitting Vetter inventors and prior art, and Vetter tried to impose exclusivity and nonchallenge terms on Regeneron.
- Regeneron brought antitrust claims (including Walker Process fraud claims) and a tortious‑interference claim; Novartis and Vetter moved to dismiss; Regeneron moved to stay the patent case pending an inter partes review (IPR) and submitted Markman briefing.
- Court adopted the parties’ agreed claim constructions, dismissed Regeneron’s antitrust and tortious‑interference claims with prejudice, and denied Regeneron’s motion to stay the patent litigation pending IPR.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Claim construction / need for Markman hearing | There is an actual dispute over the meaning of "terminally sterilized" and Novartis should be precluded from making broader arguments at trial. | Novartis submitted joint claim constructions and denied a true dispute; no separate construction needed beyond parties' submissions. | Court adopted Regeneron’s proposed constructions in full and declined to hold a Markman hearing or craft its own broader construction. |
| Antitrust claims — relevant product market | Market limited to FDA‑approved anti‑VEGF PFS; PFS are functionally distinct and not reasonably interchangeable with vials, supporting Walker Process and §2/§1 claims. | Market definition is impermissibly narrow; vials are reasonable substitutes so Regeneron fails to plead a plausible relevant market. | Court dismissed all antitrust claims for failure to plausibly define the relevant product market (claims collapsed because market mirrored the patent). |
| Tortious interference (New York law) — statute of limitations/equitable estoppel | Tolling by fraudulent concealment / equitable estoppel delayed accrual until discovery (2020), so claim is timely. | Claim accrued when the patent issued (2015) and was therefore time‑barred; alleged public deception cannot support equitable estoppel. | Court held the interference claim time‑barred; equitable estoppel unavailable because alleged misconduct was public and Regeneron had earlier notice; claim dismissed with prejudice. |
| Stay pending PTO IPR | IPR may invalidate the ’631 patent; staying will conserve resources and could simplify issues. | IPR would resolve only limited issues (e.g., obviousness), many claims remain; stay would prejudice Novartis (direct competitor) and could delay the case years. | Court denied stay: potential limited simplification did not outweigh likely prejudice and accrued discovery. |
Key Cases Cited
- Markman v. Westview Instruments, Inc., 517 U.S. 370 (court must construe patent claims as a question of law)
- Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172 (patent obtained by knowing fraud can give rise to antitrust liability)
- FTC v. Actavis, Inc., 570 U.S. 136 (patent‑based settlements may violate antitrust law in some circumstances)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standard: plausibility requirement)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (pleading standard and market‑definition requirements)
- Chapman v. N.Y. State Div. for Youth, 546 F.3d 230 (plaintiff must plead reasonable interchangeability/cross‑elasticity for market definition)
- City of N.Y. v. Group Health Inc., 649 F.3d 151 (rule of reasonable interchangeability defines product market boundaries)
- TransWeb, LLC v. 3M Innovative Props. Co., 812 F.3d 1295 (Walker Process elements and interaction with antitrust law)
- In re DDAVP Direct Purchaser Antitrust Litig., 585 F.3d 677 (patent grants do not automatically equate to antitrust liability)